Abstract PS12-04: Rintodestrant (G1 T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection - Aftimos, P; Neven, P; Pegram, M (Cancer Res, 2021)